Colombo Giorgio L, Di Matteo Sergio, Martinotti Chiara, Oselin Martina, Bruno Giacomo M, Beghi Gianfranco M
Department of Drug Sciences, University of Pavia, Pavia, Italy.
S.A.V.E. Studi Analisi Valutazioni Economiche S.r.l., Health Economics & Outcomes Research, Milan, Italy.
Clinicoecon Outcomes Res. 2018 Jan 23;10:75-82. doi: 10.2147/CEOR.S144300. eCollection 2018.
Anas barbariae hepatis et cordis extractum 200K (Oscillococcinum) is used to treat and prevent seasonal colds and airway inflammatory affections, improve symptom control, and reduce the frequency of respiratory tract infection (RTI) episodes. The objective of this controlled observational study is to investigate, from the Italian National Health Service (NHS) point of view, the role of Anas barbariae hepatis et cordis extractum 200K in preventing RTIs and estimate the annual average cost per patient due to visits and medicines in a real-world setting, investigating whether this method of treatment can bring savings for the NHS.
Data from a single center from 2002 to 2011 were used. The analysis examined 455 patients who suffered from respiratory diseases. Of the total number of patients, 246 were treated with Anas barbariae hepatis et cordis extractum 200K while 209 were not treated (Control group). All the data concerning RTI episodes, pharmacological treatments, and pneumological visits were extracted from the database.
It was found that, regardless of the diagnosis, the frequency of RTI episodes was always lower in patients treated with Anas barbariae hepatis et cordis extractum 200K; the difference between the numbers of events occurring was statistically significant in every class of patients (<0.001). The costs that the NHS had to incur were significantly lower in the classes of patients treated (<0.001).
The results indicate that Anas barbariae hepatis et cordis extractum 200K has a preventive effect on the onset of RTI episodes. The analysis shows that treating patients with Anas barbariae hepatis et cordis extractum 200K lowers costs for the NHS; this is primarily due to the fact that the medication causes fewer episodes of RTI to develop. This study suggests that the treatment with Anas barbariae hepatis et cordis extractum 200K could be helpful in preventing RTIs and improving the health status of patients who suffer from respiratory diseases, and it could lead to savings to the Italian NHS.
家鸭心肝提取物200K（ Oscillococcinum）用于治疗和预防季节性感冒及气道炎症性疾病，改善症状控制，并减少呼吸道感染（RTI）发作的频率。这项对照观察性研究的目的是从意大利国家医疗服务体系（NHS）的角度，调查家鸭心肝提取物200K在预防RTI方面的作用，并估计在实际环境中每位患者因就诊和用药产生的年度平均费用，研究这种治疗方法是否能为NHS节省开支。
使用了来自2002年至2011年单一中心的数据。该分析考察了455名患有呼吸系统疾病的患者。在患者总数中，246人接受了家鸭心肝提取物200K治疗，209人未接受治疗（对照组）。所有关于RTI发作、药物治疗和肺部就诊的数据均从数据库中提取。
研究发现，无论诊断如何，接受家鸭心肝提取物200K治疗的患者RTI发作频率始终较低；各类患者中发生事件数量的差异具有统计学意义（<0.001）。接受治疗的患者类别中，NHS必须承担的费用显著更低（<0.001）。
结果表明，家鸭心肝提取物200K对RTI发作具有预防作用。分析表明，用家鸭心肝提取物200K治疗患者可降低NHS的成本；这主要是因为该药物引发的RTI发作较少。这项研究表明，用家鸭心肝提取物200K进行治疗可能有助于预防RTI，并改善患有呼吸系统疾病患者的健康状况，还可能为意大利NHS节省开支。
